Aviso Wealth Management raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 113.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,414 shares of the medical research company's stock after purchasing an additional 1,818 shares during the quarter. Thermo Fisher Scientific accounts for 1.1% of Aviso Wealth Management's investment portfolio, making the stock its 20th largest position. Aviso Wealth Management's holdings in Thermo Fisher Scientific were worth $2,112,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of TMO. Lafayette Investments Inc. boosted its stake in shares of Thermo Fisher Scientific by 2.1% in the second quarter. Lafayette Investments Inc. now owns 830 shares of the medical research company's stock worth $459,000 after acquiring an additional 17 shares during the period. IFG Advisors LLC grew its stake in Thermo Fisher Scientific by 3.3% in the third quarter. IFG Advisors LLC now owns 532 shares of the medical research company's stock worth $329,000 after purchasing an additional 17 shares in the last quarter. Patrick M Sweeney & Associates Inc. grew its stake in Thermo Fisher Scientific by 1.8% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,031 shares of the medical research company's stock worth $570,000 after purchasing an additional 18 shares in the last quarter. Drive Wealth Management LLC boosted its position in Thermo Fisher Scientific by 0.9% during the 2nd quarter. Drive Wealth Management LLC now owns 2,123 shares of the medical research company's stock valued at $1,175,000 after acquiring an additional 18 shares in the last quarter. Finally, Quent Capital LLC lifted its holdings in shares of Thermo Fisher Scientific by 1.0% during the 2nd quarter. Quent Capital LLC now owns 1,886 shares of the medical research company's stock valued at $1,043,000 after purchasing an additional 19 shares during the last quarter. Institutional investors own 89.23% of the company's stock.
A number of brokerages recently issued reports on TMO. Sanford C. Bernstein reduced their target price on Thermo Fisher Scientific from $625.00 to $620.00 and set a "market perform" rating for the company in a research note on Thursday, October 24th. Evercore ISI reduced their price objective on Thermo Fisher Scientific from $630.00 to $620.00 and set an "outperform" rating for the company in a research note on Thursday, October 24th. Wells Fargo & Company dropped their target price on Thermo Fisher Scientific from $670.00 to $660.00 and set an "overweight" rating on the stock in a research report on Thursday, October 24th. Bank of America raised their target price on Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a "buy" rating in a research report on Monday, September 16th. Finally, Barclays dropped their target price on Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating on the stock in a research report on Wednesday, October 23rd. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $649.33.
Get Our Latest Stock Report on TMO
In related news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the sale, the executive vice president now owns 16,663 shares in the company, valued at $9,333,946.08. This represents a 1.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the business's stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the transaction, the senior vice president now directly owns 12,736 shares in the company, valued at $7,134,197.76. This represents a 13.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 37,150 shares of company stock worth $20,651,865. 0.34% of the stock is currently owned by insiders.
Shares of TMO stock opened at $513.08 on Monday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. Thermo Fisher Scientific Inc. has a fifty-two week low of $464.17 and a fifty-two week high of $627.88. The stock has a market capitalization of $196.25 billion, a P/E ratio of 32.17, a price-to-earnings-growth ratio of 3.39 and a beta of 0.79. The company has a 50 day moving average price of $586.43 and a 200 day moving average price of $582.39.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to analysts' expectations of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm's revenue was up .2% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.69 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.67 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be given a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.30%. Thermo Fisher Scientific's dividend payout ratio is presently 9.78%.
Thermo Fisher Scientific announced that its Board of Directors has approved a share buyback plan on Friday, November 15th that allows the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's management believes its shares are undervalued.
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.